Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q2 2020 Earnings Conference Call - Final Transcript
Aug 05, 2020 • 08:00 am ET
Greetings everyone and welcome to the BrainStorm Cell Therapeutics' Financial Results for the Second Quarter of 2020 and Corporate Update Conference Call. At this time, all participants are in listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator instructions] As a reminder, today's conference call is being recorded.
It is now my pleasure to introduce your host, Michael Wood of LifeSci Advisors. Sir, you may begin.
Thank you operator and thank you all for joining the BrainStorm Cell Therapeutics call today. Before we begin the opening remarks, I would like to remind listeners that this conference call contains numerous statements, descriptions, forecasts, and projections regarding BrainStorm Cell Therapeutics, and its potential future business operations and performance, statements regarding the market potential for the treatment of neurodegenerative disorders such as ALS and MS, the sufficiency of our existing capital resources for continuing operations in 2020 and beyond, the safety and clinical effectiveness of our NurOwn technology platform, clinical trials of NurOwn and related clinical development programs, as well as the ability to develop strategic collaborations and partnerships to support our business planning efforts.
Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond the Company's our control, including the risks and uncertainties described from time-to-time in our SEC filings. Results may differ material from those projected on today's call. The Company undertakes no obligation to publicly update any forward-looking statements.
Joining me on the call today will be, Chaim Lebovits, CEO of BrainStorm; Dr. Ralph Kern, President and Chief Medical Officer; David Setboun, Dr. Revital Geffen-Aricha VP of Research and Development; and Preetam Shah, EVP and Chief Financial Officer, they be available to answer your questions as well as with additional members of the management team during the Q&A session, which follows the prepared remarks.
So, I would now like to turn the call over to Mr. Lebovits, please go ahead.
Thank you, Mike. Welcome to the BrainStorm's second quarter 2020 earnings call. And thank you everyone for joining us. The onset of this call, I'm so proud to share with you that our cash on hand is by far our record for BrainStorm. We have never been in such a strong financial position. We have no debt, no convertibles or the like, we today are close to $35 million cash on hand. I will begin this morning's call with some introductory remarks and general corporate updates at BrainStorm.
Next, our President and Chief Medical Officer Dr. Ralph Kern will update you on our clinical programs including our pivotal ALS trial recently and recently announced Phase II Alzheimer's disease program and our Phase II Progressive MS trial. Following Ralph's comments Dr. Revital Aricha, our VP R&D will walk you through our development program for NurOwn derived exosome treatment for COVID-19 ARDS. Our Chief Financial Officer, Dr. Preetam Shah will then provide updates on our financial results before turning it back to me for concluding remarks. We will, of course, address your questions in the Q&A